-
Mashup Score: 0Abbott Receives FDA Approval for Minimally Invasive Portico™ with FlexNav™ TAVR System to Treat Patients with Aortic Valve Disease - 2 year(s) ago
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Portico™ with FlexNav™ transcatheter aortic valve replacement (TAVR) system to…
Source: Abbott MediaRoomCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 5Abbott's Amplatzer™ Amulet™ Device Approved by FDA to Treat People With Atrial Fibrillation at Risk of Stroke - 3 year(s) ago
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) approved the company’s Amplatzer™ Amulet™ Left Atrial Appendage Occluder to treat people with atrial…
Source: Abbott MediaRoomCategories: Cardiologists, Latest HeadlinesTweet-
Abbott's Amplatzer™ Amulet™ Device Approved by FDA to Treat People With Atrial Fibrillation at Risk of Stroke https://t.co/SFIJR6s97L
-
-
Mashup Score: 0Abbott Issues Updated 2021 Outlook - 4 year(s) ago
Abbott (NYSE: ABT) today announced an update to its financial outlook for the full-year 2021. The updated guidance is due to significantly lower recent and projected COVID-19 diagnostic testing…
Source: Abbott MediaRoomCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
$ABT said demand for COVID-19 testing is declining faster than originally expected. It cut its guidance for 2021 COVID-19 testing revenue by $2.5bn to $4.0-$4.5bn. https://t.co/5gvNTJojWA
-
-
Mashup Score: 20
Abbott (NYSE: ABT) announced today it began shipping its BinaxNOW™ COVID-19 Ag Self Test to retailers across the country. Consumers can expect the test to be available in the next few days…
Source: Abbott MediaRoomCategories: Healthcare Professionals, Latest HeadlinesTweet-
RT @megtirrell: Abbott's BinaxNOW self #covid19 test will be available in stores for $23.99 for a 2-pack: https://t.co/cKl8OetC1G
-
-
Mashup Score: 9
Abbott (NYSE: ABT) announced today it began shipping its BinaxNOW™ COVID-19 Ag Self Test to retailers across the country. Consumers can expect the test to be available in the next few days…
Source: Abbott MediaRoomCategories: Infectious Disease, Latest HeadlinesTweet-
RT @megtirrell: Abbott's BinaxNOW self #covid19 test will be available in stores for $23.99 for a 2-pack: https://t.co/cKl8OetC1G
-
-
Mashup Score: 97
[auto]
Source: Abbott MediaRoomCategories: Healthcare Professionals, Latest HeadlinesTweet-
The advent of fast, reliable, easy to use at home tests for Covid is a major achievement and will help more people self identify, isolate, and reduce the risk of transmitting infection to others. I would expect a wave of these tests to come to market now. https://t.co/tMBhH79AXV
-
-
Mashup Score: 2
[auto]
Source: Abbott MediaRoomCategories: Healthcare Professionals, Latest HeadlinesTweet-
Remarkable! Would love a complimentary telehealth service to counsel people through results but this is awesome. https://t.co/WhYgHHxegJ
-
-
Mashup Score: 1Abbott Launches First Optical Coherence Tomography Virtual Reality Training Program for Cardiologists - 4 year(s) ago
ABBOTT PARK, Ill., Dec. 9, 2020 — Abbott today announced the global release of its first virtual reality-based training program designed to change how interventional cardiologists are trained in…
Source: Abbott MediaRoomCategories: Future of Medicine, Latest HeadlinesTweet-
Abbott Launches First Optical Coherence Tomography Virtual Reality Training Program for Cardiologists https://t.co/tV4iQZ2L2p @AbbottNews
-
-
Mashup Score: 0
Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its BinaxNOW™ COVID-19 Ag Card rapid test for detection of…
Source: Abbott MediaRoomCategories: Future of Medicine, Latest HeadlinesTweet-
Since receiving emergency use authorization from the @US_FDA for its rapid response #COVID19 antigen test, @AbbottNews plans to increase production to 50 million tests a month by October. Learn more here. https://t.co/pgde1kpB2J
-
-
Mashup Score: 1
Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its BinaxNOW™ COVID-19 Ag Card rapid test for detection of…
Source: Abbott MediaRoomCategories: Future of Medicine, Latest HeadlinesTweet-
.@AbbottNews’s new low-cost, rapid #COVID19 test received @US_FDA emergency use authorization to detect the virus within days of showing symptoms. The company plans to ship out tens of millions of these tests next month. Get more information here. https://t.co/pgde1kpB2J
-
@CardioIAN #CardioTwitter https://t.co/4XxYnyx2AT